1. Status og perspektiver for behandling af de kroniske myeloproliferative neoplasier
- Author
-
Ocias, Lukas Frans, Holmström, Morten Orebo, Riley, Caroline Hasselbalch, Andersen, Christen Lykkegaard, Rønnov-Jessen, Dorthe, Starklint, Jørn, Frederiksen, Mikael, Steffensen, Morten Saabye, Bjerrum, Ole Weis, Farmer, Sarah, Mourits-Andersen, Hans Torben, Hasselbalch, Hans Carl, and Larsen, Thomas Stauffer
- Subjects
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ,Myeloproliferative Disorders/drug therapy ,Polycythemia Vera/drug therapy ,hemic and lymphatic diseases ,Janus Kinase 2/antagonists & inhibitors ,Humans ,Interferon-alpha/therapeutic use ,Thrombocytosis/drug therapy ,Algorithms ,Primary Myelofibrosis/drug therapy - Abstract
Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.
- Published
- 2015